NYMX » Topics » SIGNATURES

This excerpt taken from the NYMX 6-K filed Aug 14, 2009.

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 NYMOX PHARMACEUTICAL CORPORATION

(Registrant)




 By:  /s/ Paul Averback

 Paul Averback

 President and Chief Executive Officer





Date: August 14, 2009




 

[NYMOX logo]

This excerpt taken from the NYMX 6-K filed Jun 3, 2009.

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 NYMOX PHARMACEUTICAL CORPORATION

(Registrant)




 By:  /s/ Paul Averback                                          

 Paul Averback

 President and Chief Executive Officer





Date: May 15, 2009






 

This excerpt taken from the NYMX 6-K filed May 15, 2009.

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 NYMOX PHARMACEUTICAL CORPORATION

(Registrant)




 By:  /s/ Paul Averback                                          

 Paul Averback

 President and Chief Executive Officer





Date: May 15, 2009







This excerpt taken from the NYMX 6-K filed Apr 20, 2009.

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

NYMOX PHARMACEUTICAL CORPORATION

 

(Registrant)

 

 

 

 

 

 

 

By:  /s/ Paul Averback

 

Paul Averback

 

President and Chief Executive Officer





Date: April 20, 2009




002.990220.





This excerpt taken from the NYMX 20-F filed Mar 13, 2009.

SIGNATURES


The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.


NYMOX PHARMACEUTICAL CORPORATION

(Registrant)

 

 

 

/s/ Paul Averback

Paul Averback

Title: President



Date: March 13, 2009




115






This excerpt taken from the NYMX 6-K filed Mar 13, 2009.

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 

NYMOX PHARMACEUTICAL CORPORATION

(Registrant)




By:  /s/ Paul Averback

Paul Averback

President and Chief Executive Officer





Date: March 13, 2009









This excerpt taken from the NYMX 6-K filed Nov 14, 2008.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
                    (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: November 14, 2008

This excerpt taken from the NYMX 6-K filed Aug 13, 2008.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
          (Registrant)


 
By: /s/ Paul Averback
Paul Averback
President and Chief Executive Officer


Date: August 13, 2008

This excerpt taken from the NYMX 6-K filed May 14, 2008.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
         (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: May 14, 2008

This excerpt taken from the NYMX 20-F filed Apr 28, 2008.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf .

NYMOX PHARMACEUTICAL CORPORATION
         (Registrant)


 
/S/ Paul Averback
Paul Averback
Title: President

Date: April 28, 2008











110


EXHIBIT INDEX
NYMOX PHARMACEUTICAL CORPORATION

Form 20-F Annual Report

Exhibit No. Description

1(a)
Articles of Incorporation, as amended. (incorporated by reference to Exhibit 3.1 to the Company’s Form 20-F filed with the Commission December 9, 1996)
1(b) Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company’s Form 20-F filed with the Commission December 9, 1996)
4(a) Memorandum of Agreement between Paul Averback and the Company (incorporated by reference to Exhibit 10.1 to the Company’s Form 20-F filed with the Commission December 9, 1996)
4(b) Share Option Plan of the Company (incorporated by reference to Exhibit 10.2 to the Company’s Form 20-F filed with the Commission December 9, 1996)
4(c) Research and License Agreement between the Massachusetts General Hospital Corporation and the Company (incorporated by reference to Exhibit 10.3 to the Company’s Form 20-F filed with the Commission December 9, 1996)
4(d) Research and License Amendment between the Massachusetts General Hospital Corporation and the Company (incorporated by reference to Exhibit 10.5 to the Company’s Form 20-F filed with the Commission February 21, 1997)
4(e) Common Stock Purchase Agreement between Nymox Pharmaceutical Corporation and Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.0 to the Company’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(f) Registration Rights Agreement between Nymox Pharmaceutical Corporation and Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.1 to the Company’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(g) Escrow Agreement among Nymox Pharmaceutical Corporation, Jaspas Investments Limited and Epstein, Becker & Green, P.C. dated November 1, 1999 (incorporated by reference to Exhibit 2.2 to the Company’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(h) Stock Purchase Warrant to purchase common shares issued to Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.3 to the Company’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(i) Research and License Agreement between the Rhode Island Hospital Corporation and the Company dated May 14, 1999 (incorporated by reference to Exhibit 10.10 to the Company’s Form 20-F filed with the Commission May 15, 2000).
4(j) Research and License Amendment between the Rhode Island Hospital Corporation and the Company dated November 19, 2001 (incorporated by reference to Exhibit 10.10 to the Company’s Form 20-F filed with the Commission June 28, 2002).
4(k) Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated January 27, 2003 (incorporated by reference to Exhibit 10.0 to the Company’s F-3 Registration Statement filed with the Commission on March 12, 2003).
4(l) Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated August 25, 2003 (incorporated by reference to Exhibit 10.1 to the Company’s 6-K Report filed with the Commission on November 13, 2003).
4(m) Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated October 6, 2004 (incorporated by reference to Exhibit 10.1 to the Company’s 6-K Report filed with the Commission on November 15, 2004).
4(n) Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated October 21, 2005. (incorporated by reference to Exhibit 10.1 to the Company’s 20-F Report filed with the Commission on June 29, 2006).
4(o) Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated November 13, 2006. (incorporated by reference to Exhibit 10.1 to the Company’s 6-K Report filed with the Commission on March 15, 2007).
4(p) Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated November 16, 2007. (incorporated by reference to Exhibit 99.1 to the Company’s 6-K Report filed with the Commission on March 14, 2008).
8 List of Subsidiaries of Nymox Pharmaceutical Corporation (incorporated by reference to Exhibit 8 to the Company’s Form 20-F filed with the Commission June 30, 2004)
11 Code of Business Conduct for the Officers, Directors and Employees of Nymox Pharmaceutical Corporation (incorporated by reference to Exhibit 11 to the Company’s Form 20-F filed with the Commission June 30, 2004)
12(a) Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a)
12(b) Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a)
13(a) Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
13(b) Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

111

This excerpt taken from the NYMX 6-K filed Apr 22, 2008.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
          (Registrant)


 
By: /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: April 22, 2008

This excerpt taken from the NYMX 6-K filed Mar 14, 2008.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
          (Registrant)


 
By: /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: March 14, 2008

This excerpt taken from the NYMX 6-K filed Nov 13, 2007.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
            (Registrant)



 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: November 13, 2007

This excerpt taken from the NYMX 6-K filed Aug 14, 2007.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
            (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: August 14, 2007

This excerpt taken from the NYMX 20-F filed Jun 26, 2007.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf .

NYMOX PHARMACEUTICAL CORPORATION


 
            (Registrant)
      /S/ Paul Averback
      Paul Averback
      Title: President

Date: June 26, 2007













98


This excerpt taken from the NYMX 6-K filed May 15, 2007.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
          (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer


Date: March 15, 2007

This excerpt taken from the NYMX 6-K filed Apr 23, 2007.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
         (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: April 23, 2007

This excerpt taken from the NYMX 6-K filed Mar 15, 2007.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
                (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: March 15, 2007


This excerpt taken from the NYMX 6-K filed Nov 13, 2006.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
            (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer


Date: November 13, 2006

This excerpt taken from the NYMX 6-K filed Aug 11, 2006.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
        (Registrant)


 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer


Date: August 11, 2006

This excerpt taken from the NYMX 20-F filed Jun 30, 2006.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf .

NYMOX PHARMACEUTICAL CORPORATION
                         (Registrant)


      /S/ Paul Averback
      Paul Averback
      Title: President

Date: June 30, 2006








101


This excerpt taken from the NYMX 6-K filed May 15, 2006.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  NYMOX PHARMACEUTICAL CORPORATION
  (Registrant)
   
   
  By: /s/ Paul Averback
  Paul Averback
  President and Chief Executive Officer

Date: May 15, 2006

This excerpt taken from the NYMX 6-K filed May 11, 2006.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
(Registrant)
 
 
By: /s/ Paul Averback
      Paul Averback
      President and Chief Executive Officer

Date: May 11, 2006

This excerpt taken from the NYMX 6-K filed Nov 14, 2005.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
          (Registrant)



 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: November 14, 2005

This excerpt taken from the NYMX 6-K filed Aug 15, 2005.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
(Registrant)
    
    
By: /s/ Paul Averback             
      Paul Averback
      President and Chief Executive Officer

Date: August 15, 2005

This excerpt taken from the NYMX 20-F filed Jun 30, 2005.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant certifies that it meets all of the requirements for filing on Form 20-F and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
        (Registrant)
/S/ Paul Averback
 Paul Averback
 Title: President

Date: June 30, 2005













90


This excerpt taken from the NYMX 6-K filed May 13, 2005.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NYMOX PHARMACEUTICAL CORPORATION
          (Registrant)



 
By:  /s/ Paul Averback
Paul Averback
President and Chief Executive Officer

Date: May 13, 2005

This excerpt taken from the NYMX 6-K filed Mar 15, 2005.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


NYMOX PHARMACEUTICAL CORPORATION
(Registrant)


By:    /s/  Paul Averback
Paul Averback
President and Chief Executive Officer

Date: March 15, 2005







Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki